- •Dedication
- •Foreword
- •Preface
- •Ocular Allergy Overview
- •The ocular surface
- •Clinical examination
- •Immunopathophysiology of ocular allergy
- •Acute allergic conjunctivitis
- •Vernal keratoconjunctivitis
- •Atopic keratoconjunctivitis
- •Giant papillary conjunctivitis
- •Contact dermatitis of the eyelids
- •Blepharoconjunctivitis
- •Bacterial conjunctivitis
- •Viral conjunctivitis
- •Vasomotor conjunctivitis
- •Ocular examination
- •Ophthalmic procedures and testing
- •Summary
- •References
- •Ocular Mast Cells and Mediators
- •Mast cell mediators
- •Preformed granule-associated mediators
- •Biogenic amines
- •Proteoglycans
- •Neutral proteases
- •Newly generated mediators
- •Lipid mediators
- •Cytokines
- •Mast cell heterogeneity
- •Phenotypic heterogeneity
- •Functional heterogeneity
- •Pharmacologic heterogeneity
- •Ocular mast cells
- •The normal eye
- •Mast cells in diseases of the eye
- •Allergic conjunctivitis
- •Vernal conjunctivitis
- •Giant papillary conjunctivitis
- •Experimental autoimmune uveitis
- •Summary
- •References
- •Allergic Conjunctivitis
- •History
- •Examination
- •Seasonal and perennial allergic conjunctivitis
- •Seasonal allergic conjunctivitis
- •Perennial allergic conjunctivitis
- •Procedures
- •Late-phase reaction
- •Treatment
- •Antihistamines
- •Mast cell stabilizers
- •Lodoxamide tromethamine 0.1% (Alomide)
- •Ketorolac tromethamine (Acular)
- •Olopatadine (Patanol, Pataday)
- •Ketotifen (Zaditor)
- •Nedocromil (Alocril)
- •Pemirolast (Alamast)
- •Azelastine (Optivar)
- •Epinastine (Elestat)
- •Corticosteroids (Vexol, Lotemax)
- •Summary
- •References
- •Vernal Conjunctivitis
- •History
- •Epidemiology
- •Clinical manifestation
- •Conjunctival signs
- •Limbal signs
- •Corneal signs
- •Pathogenesis
- •Laboratory evaluation
- •Allergy testing
- •Conjunctival examination
- •Tear evaluation
- •Ocular challenge test
- •Treatment
- •Mast cell stabilizers
- •Antihistamines
- •Corticosteroids
- •Immunosuppressive agents
- •Other medical therapies
- •Surgical therapy
- •Treatment of secondary infections
- •Hyposensitization and immunotherapy
- •Prognosis
- •References
- •Giant Papillary Conjunctivitis
- •Signs and symptoms
- •Stages of giant papillary conjunctivitis
- •Stage 1: preclinical giant papillary conjunctivitis
- •Stage 2: mild giant papillary conjunctivitis
- •Stage 3: moderate giant papillary conjunctivitis
- •Stage 4: severe giant papillary conjunctivitis
- •Epidemiology
- •Histopathology
- •Coated contact lenses
- •Pathophysiology
- •Treatment
- •Treatment for stage 1: preclinical giant papillary conjunctivitis
- •Treatment for stage 2: mild giant papillary conjunctivitis
- •Treatment for stage 3: moderate giant papillary conjunctivitis
- •Treatment for stage 4: severe giant papillary conjunctivitis
- •Summary
- •References
- •Recognizing marginal dry eye disease
- •Contact lens wear in patients with dry eye
- •The use of therapeutic contact lenses in dry eye
- •The use of contact lenses in a patient with ocular allergy
- •Contact lenses and allergic reactions
- •Managing contact lens wear in the patient with ocular allergy
- •Summary of contact lens use in patient with ocular allergy
- •References
- •Mucous membrane pemphigoid
- •Clinical features
- •Diagnostic studies
- •Disease course and treatment
- •Linear immunoglobulin A disease
- •Clinical features
- •Diagnostic studies
- •Disease course and treatment
- •Epidermolysis bullosa acquisita
- •Clinical features
- •Diagnostic studies
- •Disease course and treatment
- •Ocular pemphigus vulgaris
- •Clinical features
- •Diagnostic studies
- •Disease course and treatment
- •Summary
- •References
- •Seborrheic dermatitis
- •Treatment
- •Vitiligo
- •Heliotrope rash
- •Port-wine stains
- •Xanthelasmas and plane xanthomas
- •Seborrheic keratosis
- •Skin tags
- •Warts
- •Comedones
- •Syringoma
- •Rosacea
- •Lipoid proteinosis
- •Angioedema
- •Contact urticaria
- •Erysipelas
- •Trichinosis
- •Chalazion
- •Hordeolum
- •Nevi
- •Sarcoid
- •Hemangioma
- •Basal cell carcinoma
- •Squamous cell carcinoma
- •Sebaceous carcinoma
- •Malignant melanoma
- •Eyelid dermatitis
- •Atopic dermatitis
- •Contact dermatitis
- •Acute, subacute, and chronic
- •Epidemiology
- •Irritant versus allergic
- •Etiologies
- •Irritation due to mascara and eye cosmetic preservatives
- •Fragrance
- •Irritation due to conjunctival deposition
- •Nail polish
- •Metals
- •Aeroallergens
- •Medications/eyedrops/contact lens solution
- •Paper
- •Plants
- •Histology
- •Diagnosis
- •Herpes simplex
- •Herpes zoster
- •Treatment considerations for the eyelids
- •Eyelid dermatitis
- •Infections
- •Urticaria and angiodema
- •Benign tumors and growths
- •Malignant tumors
- •‘‘Cosmetic’’ lesions of the eyelids
- •Vascular lesions
- •Vitiligo
- •Others
- •References
- •Bacterial conjunctivitis
- •Viral conjunctivitis/herpes simplex virus infections
- •Treatment of infectious conjunctivitis
- •Nasolacrimal duct obstruction
- •Allergic conjunctivitis
- •Neonatal conjunctivitis
- •Congenital glaucoma
- •Uveitis
- •References
- •Ocular Allergy Treatment
- •Ocular allergy treatment algorithm
- •Advisory nonprescription interventions
- •Environmental control
- •Cold compresses
- •Lubrication
- •Contact lenses
- •Decongestants
- •Antihistamines
- •Oral antihistamines
- •Topical antihistamines
- •Topical antihistamines
- •Levocabastine
- •Emedastine
- •Cromoglycate
- •Lodoxamide
- •Pemirolast
- •Ketorolac
- •Multiple action agents
- •Olopatadine
- •Ketotifen
- •Nedocromil
- •Azelastine
- •Epinastine
- •Mizolastine
- •Picumast
- •Amlexanox
- •Topical antihistamines and dry eye
- •Steroids
- •Ophthalmic steroids
- •Intranasal steroids
- •Immunomodulatory agents
- •Cyclosporine
- •Immunotherapy
- •Summary
- •References
94 |
DONSHIK et al |
shows infiltration of neutrophils, eosinophils, and plasma cells. The specific source of this factor has not yet been determined.
Leukotriene C4 has also been reported to be elevated in the tears of patients with GPC. This mediator’s actions on ocular tissues may be in part responsible for conjunctival injection and edema, increased mucoid secretions, and the papillary reaction that occurs in GPC [44].
The elevated levels of tear immunoglobulins, inflammatory mediators, and chemotactic factors (also found in vernal conjunctivitis) provide further evidence of an immunologic basis of GPC.
Coated contact lenses
Contact lenses rapidly develop a complex coating of various substances after insertion onto the eye. Within 30 minutes after lens insertion, 50% of the contact lens is coated, and by 8 hours, approximately 90% of the surface of the lens is coated [45,46]. Even with the best of cleaning regimens, using surfactants and enzymatic treatment, only 75% of the coating is removed. New coating material is constantly built on the surface of the contact lens [47]. Coated contact lenses are a constant feature of GPC, and as the syndrome progresses, lens coating increases. Patients find it increasingly di cult to keep their lenses clean [48]. Lenses with higher water content tend to accumulate more coating than lenses with lower water content [49–51]. Glyceryl methylmethacrylate contact lenses have been shown to accumulate less calcium deposits than HEMA contact lenses, and it is believed that these lenses may tend to coat less than HEMA lenses [52]. Silicone hydrogel contact lenses deposit less lysozyme and total protein than HEMA-based hydrogels but are more prone to lipid deposition [53,54]. Studies have shown that the nature of the deposits on lenses of patients with GPC and asymptomatic individuals are similar [55–60]. Although coating does not necessarily lead to the occurrence of GPC, patients with GPC accumulate more coating on their contact lenses than do patients who do not have GPC [48,61].
There are no morphologic or biochemical findings that can di erentiate the coating on the contact lenses of patients who have GPC from that on the lenses of those who do not have GPC [48]. When coated contact lenses from GPC patients are placed on the eyes of rhesus monkeys, however, the monkeys develop injection, thickening, and a papillary reaction on the upper tarsal conjunctiva, which resembles that seen in GPC (Fig. 9) [62]. In addition, elevated levels of IgE and IgG have been found in the tears of these monkeys who were wearing the coated contact lenses. A biopsy of the tarsal plate shows a cellular infiltrate consisting of eosinophils and plasma cells, which are similar to the infiltrates observed in biopsies from patients with GPC [62]. Contact lenses worn by patients who did not have GPC and new unworn contact lenses did not elicit the inflammatory, histologic, or immunologic changes when placed on the eyes of monkeys. It is
GIANT PAPILLARY CONJUNCTIVITIS |
95 |
Fig. 9. Upper tarsal conjunctiva of rhesus monkey after being fitted with contact lens from a patient with giant papillary conjunctivitis. Note the marked tarsal injection, thickening, and papillary reaction.
believed this animal model shows the development of GPC secondary to coated contact lenses, and strongly suggests that an antigen does exist on the coated contact lens that can simulate the inflammatory reaction seen clinically as GPC.
Pathophysiology
Although the cause of GPC is unknown, many factors seem to influence its development. The morphologic and histologic similarities between GPC and vernal conjunctivitis have led many investigators to believe that these conditions share a common pathophysiology [27]. Whether GPC is a purely immunologic disease or whether mechanical trauma or irritation are contributing factors is a matter of ongoing debate. The authors’ hypothesis of the pathophysiology of contact lens–associated GPC is as follows. Contact lenses become coated and this coating serves as an antigen stimulus. This stimulation causes the production of tear immunoglobulins, IgE, IgG, and in severe cases IgM. The complement system is also activated by the formation of C3 anaphylatoxin. C3 anaphylatoxin, in addition to IgE and some classes of IgG, can interact with mast cells and basophils, resulting in the release of vasoactive amines. The coated contact lens also cause conjunctival trauma, which results in the release of NCF and other inflammatory mediators, which attract eosinophils, mast cells, and basophils, and lymphocytes and plasma cells to the conjunctiva. These cells interact with IgG, IgE, and C3a, resulting in the release of additional inflammatory
